NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.74 +0.26 (+0.33%) GOLD FUTURES
2,323.70 -7.50 (-0.32%) DOW
38,876.91 +24.64 (+0.06%) Bitcoin GBP
50,666.46 +142.25 (+0.28%)
Moderna, Inc. (0A45.L)
| Previous close | 165.20 |
| Open | 167.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 165.36 - 170.31 |
| 52-week range | 95.06 - 217.15 |
| Volume | |
| Avg. volume | 12,058 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | 0.05 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results
Moderna, Inc. ( NASDAQ:MRNA ) just released its quarterly report and things are looking bullish. Revenues of US$167m...
- Simply Wall St.
Moderna First Quarter 2024 Earnings: Beats Expectations
Moderna ( NASDAQ:MRNA ) First Quarter 2024 Results Key Financial Results Revenue: US$167.0m (down 91% from 1Q 2023...
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
